Alert: New Earnings Report (11/2/23)-Regeneron Pharmaceuticals Inc (NASDAQ: REGN).


For its third fiscal quarter (ending September 30), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has reported a -23% decline in E.P.S. from $12.31 a year ago to $9.48 in the current quarter. This performance was $-1.36 short of the consensus estimate of $10.84. E.P.S. were $37.35 for the latest four quarters through September 30 versus $50.29 for the same period a year ago — a decline of -26%.


Recent Price Action

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) stock enjoyed a large increase of 3.5% on 11/2/23. The stock closed at $818.79. Relative to the market the stock has been strong over the last nine months and has risen 2.7% during the last week.

Current PriceTarget Research Rating

REGN is expected to continue to be an important Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.

Regeneron Pharmaceuticals has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Regeneron Pharmaceuticals has a slightly positive Appreciation Score of 64 and a slightly positive Power Rating of 67, resulting in the Positive Value Trend Rating.

Rating Review

In light of this new information and positive market action we are reviewing our current Overall Rating of B. This review will be completed in the next several days.

Be the first to comment

Leave a Reply

Your email address will not be published.